Hosted on MSN6h
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
10x Genomics downgraded to Market Perform from Outperform at Leerink
Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...
10x Genomics price target lowered to $18 from $21 at Stifel
Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...
10x Genomics Shares Tumble on Fear Over Cuts to NIH
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.